NasdaqCM:SLNOBiotechs
VYKAT XR FDA Nod and Phase 3 Data Could Be A Game Changer For Soleno Therapeutics (SLNO)
In January 2026, Soleno Therapeutics reported preliminary unaudited fourth-quarter 2025 net revenue guidance of US$90,000,000 to US$92,000,000 and highlighted peer-reviewed publication of pivotal VYKAT XR trial data in Prader-Willi syndrome.
The JCEM publication and confirmation that VYKAT XR is the first FDA-approved treatment for hyperphagia in Prader-Willi syndrome underscore the clinical and regulatory significance of this therapy for a previously untreated symptom burden.
We’ll now...